LifeCell International Pvt. Ltd is described in the article as an Indian stem cell bank. The company's core offering is stem cell banking services. The article states the company has raised ₹225 crore in a fundraise. That amount is reported in the headline as roughly $30 million. The investor named in the report is healthcare investment firm OrbiMed Asia Partners IV. The article does not provide operating metrics, use of proceeds, or future plans. LifeCell International, founded in 2004, preserves stem cells from umbilical cord and menstrual blood for use in treating blood-related disorders. It operates a central processing and storage facility in Chennai with a backup unit in Gurgaon and runs 111 collection centres across India. The company has serviced over 65,000 clients and is also present in the UAE. LifeCell expects to close the financial year with a turnover of Rs 100 crore. The company plans to use new funding to boost market awareness, increase distribution and staff across India, and expand into West Asia, Sri Lanka, Bangladesh and East Asia. Promoters Mayur Abhaya, Abhaya Kumar and R. Thiagarajan continue to hold the majority stake, while Bennett Coleman is a minority investor.

Total raised

$37M

Funding rounds

2

Latest round

Equity

Latest activity

Sep 2021